Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | March 17, 2011 |
| End Date: | March 2021 |
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
The investigators are researching patients with diseases of their plasma cells in order to
improve their quality and length of life. The investigators have created a database of
patient information, blood samples, and bone marrow tissue in order to achieve the following
three goals:
- Surveillance: The investigators want to track what treatments patients get or don't get,
how effective they are, how they feel, what complications they suffer, how long they
stay in remission, and how long they live.
- Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed
in the state of Ohio each year, patients often feel they don't have accurate
information. The investigators want to provide them access to our clinical team (both
phone and email consultations, even office visits for patients that can come to
Columbus) as well as information regarding informational events pertaining to your
disease and local support groups.
- Research: Because nearly all myeloma and amyloid patients relapse and treatment is
eventually unsuccessful, our focus is to develop more effective treatments that not only
prolong life, but cure the disease. Periodically the investigators will inform them
about clinical trials studying new drugs or treatment paradigms.
improve their quality and length of life. The investigators have created a database of
patient information, blood samples, and bone marrow tissue in order to achieve the following
three goals:
- Surveillance: The investigators want to track what treatments patients get or don't get,
how effective they are, how they feel, what complications they suffer, how long they
stay in remission, and how long they live.
- Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed
in the state of Ohio each year, patients often feel they don't have accurate
information. The investigators want to provide them access to our clinical team (both
phone and email consultations, even office visits for patients that can come to
Columbus) as well as information regarding informational events pertaining to your
disease and local support groups.
- Research: Because nearly all myeloma and amyloid patients relapse and treatment is
eventually unsuccessful, our focus is to develop more effective treatments that not only
prolong life, but cure the disease. Periodically the investigators will inform them
about clinical trials studying new drugs or treatment paradigms.
The investigators propose to contact and interact with all patients with plasma cell
dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical
Center) for both surveillance and research purposes in order to develop interventions
targeted to decrease their morbidity and mortality.
dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical
Center) for both surveillance and research purposes in order to develop interventions
targeted to decrease their morbidity and mortality.
Inclusion:
Diagnosis of a plasma cell dyscrasia
Exclusion:
Prisoners are excluded from participation as they have no standard access to the Ohio State
myeloma clinic and would impede the research objective of this protocol.
We found this trial at
1
site
Columbus, Ohio 43210
Principal Investigator: Ashley Rosko, MD
Phone: 614-293-3818
Click here to add this to my saved trials
